Sanofi (NASDAQ: SNY) announced that China’s National Medical Products Administration (NMPA) has approved a new indication application for dupilumab (trade name: Dupixent), for use in combination with intranasal corticosteroids in the treatment of adolescents aged 12 and older and adults with chronic rhinosinusitis with nasal polyps (CRSwNP) whose disease is inadequately controlled by systemic corticosteroids and/or surgery — making it the first biologic in China to simultaneously cover both adult and adolescent patients with CRSwNP.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | New indication expansion |
| Product | Dupixent (dupilumab) – fully human monoclonal antibody |
| Indication | CRSwNP inadequately controlled by systemic corticosteroids and/or surgery |
| Population | Adolescents aged 12 and older and adults – first biologic in China covering both age groups in CRSwNP |
| Regimen | In combination with intranasal corticosteroids |
| Approval Date | Announced 4 Nov 2026 |
Drug Profile & Mechanism of Action
- Molecule: Dupilumab (Dupixent), a fully human monoclonal antibody — not an immunosuppressant.
- Target: Inhibits the signaling of the interleukin‑4 (IL‑4) and interleukin‑13 (IL‑13) pathways, the key drivers of type 2 inflammation.
- Mechanism Validation: Across multiple Phase III clinical trials in Dupixent’s development program, the drug demonstrated significant clinical benefits by inhibiting type 2 inflammation, confirming the central role of IL‑4 and IL‑13 in various related comorbidities (specific trial data not disclosed in this announcement).
- Collaboration Structure: Jointly developed by Regeneron and Sanofi under a global collaboration agreement.
Global Franchise – Multi‑Indication Footprint
To date, Dupixent has received regulatory approval for one or more indications in over 60 countries, treating patients across various age groups in:
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Eosinophilic esophagitis (EoE)
- Prurigo nodularis
- Chronic spontaneous urticaria (CSU)
- Chronic obstructive pulmonary disease (COPD)
- Bullous pemphigoid (BP)
- Allergic fungal rhinosinusitis (AFRS)
Market Impact & Outlook
- First‑Mover Age Coverage: As the first biologic in China to cover both adult and adolescent CRSwNP patients, Dupixent secures a differentiated position in a market where younger patients previously had no approved biologic option for inadequately controlled disease.
- Beyond Surgery and Steroids: For patients failing systemic corticosteroids and/or surgery, the approval addresses a substantial unmet need — recurrent nasal polyps drive repeated surgical interventions and steroid exposure, which a type 2 inflammation–targeted biologic seeks to reduce.
- China Specialty Care Expansion: The new indication deepens Sanofi’s immunology franchise in China, adding CRSwNP to the established atopic dermatitis and asthma populations already served by Dupixent.
- Comorbidity Synergy: With type 2 inflammatory conditions frequently co‑occurring, the broad multi‑indication footprint reinforces Dupixent’s positioning as a platform therapy across the type 2 inflammation spectrum.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of Dupixent in China, market adoption of the new CRSwNP indication, and the continued expansion of the dupilumab franchise. Actual results may differ materially due to risks including reimbursement dynamics, market adoption, competitive developments, and regulatory requirements.-Fineline Info & Tech
